Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Harley-Davidson Inc (HOG) vs Zoetis Inc (ZTS) Price & Performance

Harley-Davidson IncTrade
Zoetis IncTrade

Price performance (Past 24H)

Key statistics

Harley-Davidson Inc vs Zoetis Inc — how do they compare? Harley-Davidson Inc trades at $26.75 (market cap $2.78B), while Zoetis Inc trades at $73.27 (market cap $30.20B). The key difference: Zoetis Inc is far larger — about 10.9× Harley-Davidson Inc's market cap, and Zoetis Inc pays the higher dividend (2.9%). Which is the better fit depends on your goals — on Pluang, investors hold Harley-Davidson Inc for 91 Days and Zoetis Inc for 70 Days on average.

HOGZTS
Market Cap
$2.78B$30.20B
Volume
2,966,3896,175,327
Sector
Consumer CyclicalHealth
52-Week High
$28.46$147.53
52-Week Low
$17.19$69.09
Typical Hold Time
91 Days70 Days
Enterprise Value
$3.20B$37.76B
Dividend Yield
2.8%2.9%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Harley-Davidson Inc

Harley-Davidson (HOG) trades at $26.95, up 0.04% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $28.50. Recent Q2 2026 earnings beat expectations, but revenue has declined from $5.8B in 2022 to $4.5B in 2025, with net income margin falling to 7.57%. The company maintains a dividend and shows improved cash flow trends, though it faces headwinds from tariffs and a recent data breach investigation.

The stock presents a mixed outlook: valuation metrics like P/E of 14.97 and P/B of 0.9 suggest potential upside, but declining profitability and competitive pressures pose risks. Investor sentiment is cautious with 61% hold ratings, while institutional activity shows mixed positioning. Key catalysts include execution of the 'Back to the Bricks' strategy, though tariff exposures and softening demand remain concerns.

Zoetis Inc

Zoetis (ZTS) trades at $71.55, showing modest daily gains of 0.32% amid a challenging market environment. The stock faces bearish technical signals with mixed quarterly earnings performance - beating expectations in Q2 2026 but missing in Q1. Strong fundamentals persist with 71.67% gross margins and 27.69% net income margins, though recent headwinds include U.S. companion animal market weakness and increased competition in key therapeutic areas. The company maintains robust cash flow generation with $2.9 billion from operations in 2025.

Despite near-term pressures, ZTS presents value opportunity with attractive valuation at 11.67 P/E ratio and consensus price target of $87.33 suggesting 22% upside. Risks include ongoing competitive pressures and U.S. market softness, but industry-leading profitability and international growth provide stability. Analyst sentiment remains positive with no sell ratings among 32 covering firms, though technical indicators suggest cautious near-term positioning.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Harley-Davidson Inc

Harley-Davidson is a global leading manufacturer of heavyweight motorcycles, merchandise, parts, and accessories. It sells custom, cruiser, and touring motorcycles and offers a complete line of Harley-Davidson motorcycle parts, accessories, riding gear, and apparel, as well as merchandise. Harley-Davidson Financial Services provides wholesale financing to dealers and retail financing and insurance brokerage services to customers. Harley has historically captured about half of all heavyweight domestic retail motorcycle registrations, a metric it had ceded in 2020 as it repositioned the business, but a level it is working back toward. In recent years the firm has expanded into the adventure touring market with its Pan America model and into electric with the LiveWire brand.

Read more on HOG →

About Zoetis Inc

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Read more on ZTS →